Filing Flows

Filing Flows › Celldex Therapeutics (CLDX) › Next earnings date

Celldex Therapeutics (CLDX) earnings: beat the estimate

Celldex Therapeutics (CLDX) reported on Nov 5, 2026 and beat the EPS estimate: −$0.96 against −$1.01 (+5.0%). It beat the EPS estimate in 40% of the quarters on record.

Last result+5.0% vs estimate
Beat rate40%

The last report

Celldex Therapeutics reported revenue of $22K for the second quarter 2026 (-97% Y/Y), net loss $73.5M: Contracts and grants $15K, Product development and licensing agreements $7K. How it makes money → · Every quarter →

Celldex Therapeutics: EPS against the estimate, last 5 reportsCelldex Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.89−$1.01Nov 25−$1.00−$1.22Feb 26−$1.13−$1.18May 26−$1.06−$0.94Aug 26−$1.01−$0.96Nov 26
Latest (Nov 26): Estimate −$1.01, Reported −$0.96.

Celldex Therapeutics' latest quarter

Celldex Therapeutics, Q2 2026: revenue $22K (-97% year over year), net loss $73.5M, operating cash flow −$57.4M. The chart follows the revenue to costs, profit and cash.

Questions

Did Celldex Therapeutics beat earnings?

Celldex Therapeutics (CLDX) reported on Nov 5, 2026 and beat the EPS estimate: −$0.96 against −$1.01 (+5.0%).

When does CLDX report earnings?

The next date is not set yet.

Does Celldex Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 40% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.